In a special episode of "Lung Cancer Considered," our CSO, Chandra P Belani MD, speaks with Stephen V Liu, MD about the #lungcancer research presented at the ASCO virtual meeting last weekend. #LCSM #ASCO20 Listen to the full eps. --> bit.ly/3eMY2xK

#ASCO20 take home for me: science and great drugs continue to move into earlier stage lung cancer. We need to broadly test these patients now. #lcsm

“INJUSTICE ANYWHERE IS A THREAT TO JUSTICE EVERYWHERE.” -Martin Luther King Jr. We believe our global community’s greatest strength lies in the diversity of its people. #LCSM Read our equality statement: bit.ly/3dP3mRn.

Ho hum Laird Cameron

If you work in the field of #lungcancer, you don't want to miss this! chadi nabhan MD, MBA, FACP leading a fantastic debate on #ADAURA between H. Jack West, MD, FASCO and Nathan A. Pennell MD, PhD, FASCO. Thought-provoking discussion, timely topic and top-notch panelists. Check out #OutspokenOncology on soundcloud! 👇👇👇

I'm no more negative than everyone else; I'm just the only one who would articulate it directly. It's unequivocally pos trial, but result will have NO clinical impact, which was prevailing view of all. Sintilimab was similarly inconsequential vs. current standards.

Hey hey Laird Cameron Prof. Chris Jackson !!!

November is Lung Cancer Awareness month! Let us all work together to raise awareness and dispel the nihilism that still exists against lung cancer. ⁦Jill Feldman⁩ ⁦@Pattybeatslungc⁩ ⁦Winship Cancer Institute of Emory University⁩

There are 2 risk factors for lung cancer 1. Lungs 2. A pulse

Lung cancer is a complex disease w/many causes; Largely overlooked is the relationship between air pollution & #lungcancer. We support advocacy for clean air & urge health care organizations & relevant legislative bodies to support our policy statement: bit.ly/36HUqPm

From their network meta-analysis of Asian pts w/ advanced EGFR L858R NSCLC, Chan et al. indicated no overall survival benefit from first-line EGFR TKIs and combination therapies vs. conventional chemotherapies bit.ly/3JXhhUw JTO & JTO CRR @OncologyAdvance #JTOCRR #LCSM

Am I using this meme of Antony Bridgerton in a trainee clinical talk about lung cancer with reference to oncologists and molecular testing in NSCLC? Why yes I am 💕😂 #oncmeded #lcsm #womeninmedicine Bridgerton HOJournalClub Hematology & Oncology Women Physicians Group—HOWPG

Early Registration for #WCLC22 closes on May 4, 2022! Join the world's largest international gathering of clinicians, researchers, & scientists in the field of #lungcancer & thoracic oncology. Register today: ow.ly/XObl50ISMNz #LCSM

#LungCancer screening in the US: primary care physicians’ knowledge, practices and perceived barriers. The survey by Kota et al. indicated cost, insurance and awareness as top barriers. ow.ly/pkOB50IRwQt #JTOCRR #LCSM #LDCT JTO & JTO CRR @OncologyAdvance

Improved pathologic staging starts with better communication and other multidisciplinary efforts. Mary Beth Beasley, MD, explores the topic in ILCN: bit.ly/3KrrcC1 MountSinai Pathology #LCSM

The inspiring @NarjustDumaMD cites “being human” as her greatest credential as an oncologist, explaining that reducing cancer care disparities begins with an honest assessment of our own biases/less patient-blaming (e.g. “non-compliant” may be code for poor medical communication)

Entrectinib prolonged survival in #ROS1 TKI-naïve pts w/ ROS1+ #NSCLC according to an updated integrated analysis by Drilon et al. Modest efficacy observed in pts w/ CNS-only progression post-crizotinib bit.ly/3MWtE5h #JTOCRR #LCSM JTO & JTO CRR @OncologyAdvance

It had to be done: #ASCO22 bingo

Our latest paper on ‘Incidental findings in low dose CT lung cancer screening of high-risk smokers’. Data from our initial pilot study which has helped us develop more robust protocols for management of incidental findings locally lungcancerjournal.info/article/S0169-… #lungcancer #screening

i.stuff.co.nz/pou-tiaki/1302…